The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | Multisystem immune-related AEs with immunotherapy in NSCLC
Jarushka Naidoo, MBBCh, MHS, Beaumont Hospital, Dublin, Ireland, gives an overview of a study investigating immune-related adverse events (AEs) associated with immune checkpoint inhibitor therapy for the treatment of non-small cell lung cancer (NSCLC). The study aimed to determine the proportion of patients with lung cancer who developed multisystem immune-related AEs, to identify unique features in these patients and to investigate associations with patient outcomes. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Jarushka Naidoo, MBBCh, MHS, has received research funding from AstraZeneca and Merck; has participated in a consultancy role or advisory board for AstraZeneca, Merck, BMS, Takeda, Pfizer, Roche/Genentech, and Daiichi Sankyo; and has received honoraria from AstraZeneca, Merck, BMS, Takeda, Pfizer, Roche/Genentech and Daiichi Sankyo.
